Urinary Incontinence - Pipeline Review, H2 2018

  • ID: 4592418
  • Report
  • 86 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Beech Tree Labs Inc
  • Crystec Ltd
  • Fate Therapeutics Inc
  • GTx Inc
  • Ipsen SA
  • MORE
Urinary Incontinence - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Pipeline Review, H2 2018, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.

Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.

Report Highlights:

This latest pipeline guide Urinary Incontinence - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 6, 1, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Beech Tree Labs Inc
  • Crystec Ltd
  • Fate Therapeutics Inc
  • GTx Inc
  • Ipsen SA
  • MORE
Introduction

Report Coverage

Urinary Incontinence - Overview

Urinary Incontinence - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Urinary Incontinence - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Urinary Incontinence - Companies Involved in Therapeutics Development

Allergan Plc

Beech Tree Labs Inc

Crystec Ltd

Fate Therapeutics Inc

FemmePharma Global Healthcare Inc

GTx Inc

Innovacell Biotechnologie AG

Ipsen SA

Mylan NV

Pfizer Inc

Saniona AB

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Taris Biomedical LLC

Urinary Incontinence - Drug Profiles

abobotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTL-hs - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Gastrointestinal Disorders, Ischemic Heart Failure and Urological Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enobosarm - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FT-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gtx-027 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICES-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

litoxetine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prof-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize 5-HT2C for Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NET for Stress Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate kV7 for Epilepsy, Pain and Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-303 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tolterodine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trospium chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Urinary Incontinence - Dormant Projects

Urinary Incontinence - Discontinued Products

Urinary Incontinence - Product Development Milestones

Featured News & Press Releases

May 18, 2018: GTx Updates Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at 2018 AUA Annual Meeting

Apr 16, 2018: GTx to Present Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at a Podium Presentation at 2018 AUA Annual Meeting

Apr 09, 2018: GTx Announces Early Completion of Patient Enrollment in the ASTRID Trial, a Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence

Mar 05, 2018: GTx Announced New Data Demonstrating Enobosarm's Potential to Treat Stress Urinary Incontinence at SUFU 2018

Feb 22, 2018: GTx Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence Accepted for Podium Presentation at SUFU

Jan 11, 2018: Sleep quality improves with help of incontinence drug

Sep 21, 2017: GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York City

Sep 13, 2017: GTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence

Jun 12, 2017: GTx Announces Positive Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence

May 11, 2017: GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society Annual Meeting

Jul 18, 2016: BioLife Solutions Products Embedded in Cook MyoSite Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence

May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego

Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-024 (enobosarm) on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting

Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-027 on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting

Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Urinary Incontinence, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Urinary Incontinence - Pipeline by Allergan Plc, H2 2018

Urinary Incontinence - Pipeline by Beech Tree Labs Inc, H2 2018

Urinary Incontinence - Pipeline by Crystec Ltd, H2 2018

Urinary Incontinence - Pipeline by Fate Therapeutics Inc, H2 2018

Urinary Incontinence - Pipeline by FemmePharma Global Healthcare Inc, H2 2018

Urinary Incontinence - Pipeline by GTx Inc, H2 2018

Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H2 2018

Urinary Incontinence - Pipeline by Ipsen SA, H2 2018

Urinary Incontinence - Pipeline by Mylan NV, H2 2018

Urinary Incontinence - Pipeline by Pfizer Inc, H2 2018

Urinary Incontinence - Pipeline by Saniona AB, H2 2018

Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2018

Urinary Incontinence - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Urinary Incontinence - Pipeline by Taris Biomedical LLC, H2 2018

Urinary Incontinence - Dormant Projects, H2 2018

Urinary Incontinence - Dormant Projects, H2 2018 (Contd..1), H2 2018

Urinary Incontinence - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Urinary Incontinence, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allergan Plc
  • Beech Tree Labs Inc
  • Crystec Ltd
  • Fate Therapeutics Inc
  • FemmePharma Global Healthcare Inc
  • GTx Inc
  • Innovacell Biotechnologie AG
  • Ipsen SA
  • Mylan NV
  • Pfizer Inc
  • Saniona AB
  • Taiho Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Taris Biomedical LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll